Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 67

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 67
---
5550(a)(2). The notice has no immediate effect on the listing or trading of our Common Stock, and the Common Stock will continue to trade
on The Nasdaq Capital Market under the symbol “BIAF.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have a compliance
period of 180 calendar days, or until August 6, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). Compliance may be achieved
without further action if the closing bid price of our Common Stock is at or above $1.00 for a minimum of ten consecutive business days
at any time during the 180-day compliance period, in which case Nasdaq will notify us if it determines we are in compliance and the matter
will be closed; however, Nasdaq may require the closing bid price to equal or to exceed the $1.00 minimum bid price requirement for more
than 10 consecutive business days before determining that a company complies.

If, however, we do not achieve compliance with the
Minimum Bid Price Requirement by August 6, 2025, we may be eligible for additional time to comply. In order to be eligible for such additional
time, we will be required to meet the continued listing requirements for market value of publicly held shares and all other initial listing
standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and must notify Nasdaq in writing of
our intention to cure the deficiency during the second compliance period. We intend to actively monitor the bid price of our Common Stock
and will consider available options to regain compliance with the Nasdaq listing requirements.

| 30 |

If we fail to satisfy the continued listing requirements
of The Nasdaq Capital Market, such as the corporate governance requirements, the stockholder’s equity requirement, or the minimum
closing bid price requirement, The Nasdaq Capital Market may take steps to de-list our Common Stock or Tradeable Warrants. Such a de-listing
or even notification of failure to comply with such requirements would likely have a negative effect on the price of our Common Stock
and Tradeable Warrants and would impair the ability to sell or purchase our Common Stock when you wish to do so. In the event of a de-listing,
we would take actions to restore our compliance with The Nasdaq Capital Market’s listing requirements, but we can provide no assurance
that any such action taken by us would allow our Common Stock to become listed again